Literature DB >> 22426899

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.

Luca Richeldi1, Christopher J Ryerson, Joyce S Lee, Paul J Wolters, Laura L Koth, Brett Ley, Brett M Elicker, Kirk D Jones, Talmadge E King, Jay H Ryu, Harold R Collard.   

Abstract

BACKGROUND: Decline in forced vital capacity (FVC) over time reliably predicts mortality in patients with idiopathic pulmonary fibrosis. The use of this measure in clinical practice is recommended by current evidence-based guidelines. It is unknown if the method of calculating decline in FVC (relative vs. absolute change) impacts its frequency or its ability to predict mortality.
METHODS: Patients with idiopathic pulmonary fibrosis from two prospective cohorts were included if they had a baseline and 12-month follow-up FVC. A ≥10% decline in FVC from baseline was calculated in two ways: a relative decline of 10% (e.g., from 60% predicted to 54% predicted) and an absolute decline of 10% (e.g., from 60% predicted to 50% predicted). The frequency of a ≥10% decline in FVC and its ability to predict 2-year transplant-free survival were compared between these two methods. Declines in FVC of ≥5% and ≥15% were similarly compared. Analyses were performed unadjusted and adjusted for age, gender, use of oxygen, baseline FVC and baseline diffusion capacity for carbon monoxide.
RESULTS: The frequency of any given FVC decline was significantly greater using the relative change in FVC method. For ≥10% decline, both methods predicted 2-year transplant-free survival with similar accuracy, and remained significant predictors after adjusting for baseline characteristics. The absolute change method appeared more predictive for ≥5% decline.
CONCLUSIONS: Using the relative change in FVC maximises the chance of identifying a ≥10% decline in FVC without sacrificing prognostic accuracy. This may not hold true for ≥5% decline in FVC. These findings have important implications for clinical practice and the design of clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 22426899     DOI: 10.1136/thoraxjnl-2011-201184

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  49 in total

1.  Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Williamson Z Bradford; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; David Kardatzke; Talmadge E King; Lisa H Lancaster; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Jeffrey J Swigris; Paul W Noble
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?

Authors:  Karishma Hosein; Jamie Le; Marco Mura
Journal:  Lung       Date:  2016-11-17       Impact factor: 2.584

3.  3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.

Authors:  Ranu Surolia; Fu Jun Li; Zheng Wang; Huashi Li; Gang Liu; Yong Zhou; Tracy Luckhardt; Sejong Bae; Rui-Ming Liu; Sunad Rangarajan; Joao de Andrade; Victor J Thannickal; Veena B Antony
Journal:  JCI Insight       Date:  2017-01-26

4.  Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis.

Authors:  Anna P Lam; Jose D Herazo-Maya; Joseph A Sennello; Annette S Flozak; Susan Russell; Gökhan M Mutlu; G R Scott Budinger; Ramanuj DasGupta; John Varga; Naftali Kaminski; Cara J Gottardi
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

5.  Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Eva Brunnemer; Julia Wälscher; Svenja Tenenbaum; Julia Hausmanns; Karen Schulze; Marianne Seiter; Claus Peter Heussel; Arne Warth; Felix J F Herth; Michael Kreuter
Journal:  Respiration       Date:  2018-02-28       Impact factor: 3.580

6.  Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.

Authors:  Margaret L Salisbury; Meng Xia; Yueren Zhou; Susan Murray; Nabihah Tayob; Kevin K Brown; Athol U Wells; Shelley L Schmidt; Fernando J Martinez; Kevin R Flaherty
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

7.  Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Authors:  Jennifer M Wang; Scott H Robertson; Ziyi Wang; Mu He; Rohan S Virgincar; Geoffry M Schrank; Rose Marie Smigla; Thomas G O'Riordan; John Sundy; Lukas Ebner; Craig R Rackley; Page McAdams; Bastiaan Driehuys
Journal:  Thorax       Date:  2017-08-31       Impact factor: 9.139

8.  Predicting pulmonary fibrosis disease course from past trends in pulmonary function.

Authors:  Shelley L Schmidt; Nabihah Tayob; Meilan K Han; Christopher Zappala; Dolly Kervitsky; Susan Murray; Athol U Wells; Kevin K Brown; Fernando J Martinez; Kevin R Flaherty
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

Review 9.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

10.  Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.

Authors:  Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.